603
Views
12
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

NT-proBNP on Cobas h 232 in point-of-care testing: Performance in the primary health care versus in the hospital laboratory

, , , , , , , , , , , , & show all
Pages 602-609 | Received 11 Mar 2015, Accepted 13 Jun 2015, Published online: 11 Aug 2015

References

  • Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330–7.
  • Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma t, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–40.
  • Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976–82.
  • Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Steg G, Westheim A, Knudsen CW, Perez A, Kazanegra R, Bhalla V, Herrmann HC, Aumont MC, McCullough PA. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004; 147:1078–84.
  • Clerico A, Carlo Zucchelli G, Pilo A, Passino C, Emdin M. Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin Chem Lab 2006;44:366–78.
  • Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009;5: 471–87.
  • Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, MCGill C, Katten D, Heller G. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92: 628–31.
  • Schou M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 2007;28:177–82.
  • Lepoutre T, Rousseau MF, Ahn SA, Gruson D. Measurement Nt-proBNP circulating concentrations in heart failure patients with a new point-of-care assay. Clin Lab 2013;59: 831–5.
  • Melin J, Rundstrom G, Peterson C, Bakker J, MacCraith BD, Read M, Ohman O, Jonsson C. A multiplexed point-of-care assay for C-reactive protein and N-terminal pro-brain natriuretic peptide. Anal Biochem 2011;409:7–13.
  • Jungbauer CG, Kaess B, Buchner S, Birner C, Lubnow M, Resch M, Debl K, Buesing M, Zerback R, Riegger G, Luchner A. Equal performance of novel N-terminal proBNP (Cardiac proBNP(R)) and established BNP (Triage BNP®) point-of-care tests. Biomark Med 2012;6:789–96.
  • Bertsch T, Chapelle JP, Dempfle CE, Giannitsis E, Schwabs M, Zerback R. Multicentre analytical evaluation of a new point-of-care system for the determination of cardiac and thromboembolic markers. Clin Lab 2010;56:37–49.
  • Alehagen U, Janzon M. A clinician's experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting. Eur J Heart Fail 2008;10:260–6.
  • Lee-Lewandrowski E, Januzzi JL, Green SM, Tannous B, Wu AH, Smith A, Wong A, Murakami MM, Kaczmarek J, Apple FS, Miller WL, Hartman K, Jaffe AS. Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. Clin Chem Acta 2007; 386:20–4.
  • Leistner DM, Klotsche J, Pieper L, Palm S, Stalla GK, Lehnert H, Silber S, Marz W, Wittchen HU, Zeiher AM. Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study. Clin Res Cardiol 2013;102:259–68.
  • Alehagen U, Dahlstrom U, Rehfeld JF, Goetze JP. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. J Card Fail 2013; 19:31–9.
  • Agvall B, Alehagen U, Dahlstrom U. The benefits of using a heart failure management programme in Swedish primary healthcare. Eur J Heart Fail 2013;15:228–36.
  • Verdu JM, Comin-Colet J, Domingo M, Lupon J, Gomez M, Molina L, Casacuberta JM, Munoz MA, Mena A, Brugvera-Cortada J. Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. Rev Esp Cardiol 2012;65:613–9.
  • Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McMAnus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol 2009;13:1–207.
  • De Bievre P. The 2007 International Vocabulary of Metrology (VIM), JCGM 200:2008 [ISO/IEC Guide 99]: Meeting the need for intercontinentally understood concepts and their associated intercontinentally agreed terms. Clin Biochem 2009;42:246–8.
  • Burnett RW. Accurate estimation of standard deviations for quantitative methods used in clinical chemistry. Clin Chem 1975;21:1935–8.
  • Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, Minchinela J, Perich C, Simon M. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab. 1999;59:491–500.
  • Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, Pagani F, Christenson RH, Jaffe AS. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486–93.
  • Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, Sedor FA, Butch AW. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107–15.
  • Simundic AM, Lippi G. Preanalytical phase – a continuous challenge for laboratory professionals. Biochem Med 2012; 22:145–9.
  • Narayanan S. The preanalytic phase. An important component of laboratory medicine. Am J Clin Pathol 2000; 113:429–52.
  • Martin J, Schuster T, Moessmer G, Kochs EF, Wagner KJ. Alterations in rotation thromboelastometry (ROTEM(R)) parameters: point-of-care testing vs analysis after pneumatic tube system transport. Br J Anaesth 2012;109:540–5.
  • Meesters MI, Vonk AB, van de Weerdt EK, Kamminga S, Boer C. Level of agreement between laboratory and point-of-care prothrombin time before and after cardiopulmonary bypass in cardiac surgery. Thromb Res 2014;133:1141–4.
  • Chacko B, Peter JV, Patole S, Fleming JJ, Selvakumar R. Electrolytes assessed by point-of-care testing – are the values comparable with results obtained from the central laboratory? Indian J Crit Care Med 2011;15:24–9.
  • Khezri BS, Carlsson L, Larsson A. Evaluation of the Alere NT-proBNP Test for Point of Care Testing. J Clin Lab Anal 2015.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.